ARCHWAY at AAO
The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year\u2019s AAO Annual Meeting. Nancy Holekamp, MD, sits down with\xa0NRR\xa0to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.\xa0\n\nThis editorially independent podcast is supported with advertising.